Articles about Juno

Ramp acquires Juno, a corporate travel expense startup backed by Madrona

Juno raised a $2 million seed round last year led by Seattle-based Madrona along with Bungalow Ventures. Read More

Seattle startup introduces ‘Juno,’ a digital assistant to handle admin tasks for mental health clinicians

Alpyne Labs created its AI-powered tool to take care of benefits checks, billing, scheduling, notes organization and more to free up therapists to concentrate on patient care. Read More

Madrona backs new startup tackling corporate guest travel

Juno, a platform designed to help manage corporate guest travel, raised $2 million in seed funding, the company announced Tuesday.… Read More

Ex-Amazon designers dream up $148 cardboard bassinet, and sleep better with sustainable solution

Two industrial designers who helped create and launch the first Amazon Go cashierless convenience store have a new baby, as… Read More

Led by former Juno and Alder exec, Seattle neurology startup Eliem Therapeutics raises $80M

New funding: Eliem Therapeutics, a new Seattle biotech startup led by former Juno Therapeutics exec Bob Azelby, raised $80 million… Read More

Tech Moves: Microsoft’s new executive VP; Puppet preps for IPO; Vacasa adds tech vets to board

— Microsoft added to its senior leadership team with the appointment of Christopher Young as executive vice president of business… Read More

Tech Moves: Ex-Juno CEO Hans Bishop takes over at Grail; Amazon Business chief departs; Shyft co-founder jumps to Ally; and more

— The former head of Juno Therapeutics, Hans Bishop, signed on as CEO of Grail, a Bay Area biotech focused… Read More

Juno Therapeutics’ giant new Seattle HQ is designed to destroy cancer

When you walk into Juno Therapeutics‘ new headquarters in Seattle, your eyes are immediately drawn to the view. The office’s… Read More

Juno Therapeutics’ revenue surges on Celgene partnership, loss increases on R&D spending

Seattle-based biotech juggernaut Juno Therapeutics delivered mixed results in its 2017 quarter one earnings report Thursday — the first financial report… Read More

Tech Moves: ReplyYes adds to executive team; Juno announces new leaders; and more

ReplyYes, a fast-growing, chat-based commerce startup, announced three additions to the company’s executive board this week: former Zulily engineer Trevor Inman,… Read More

Juno Therapeutics continues aggressive push toward cancer therapies as cash burn rate accelerates to $59.5 million

Juno Therapeutics, which spun out of Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children’s Research Institute… Read More

Seattle biotech investor Robert Nelsen named to Midas List of top performing VCs, propelled by early investment in Juno

Robert Nelsen may not be a household name in venture capital circles — certainly not the way that Reid Hoffman,… Read More

A perception problem: Seattle’s biotech industry should not be a hidden secret

Seattle is well known for making airplanes, coffee and software. But when it comes to cutting-edge biotechnology and health services,… Read More

Juno CEO Hans Bishop: The $1 billion Celgene deal could be the ‘most productive’ collaboration in biotech

Juno Therapeutics is no stranger to huge financing deals. The Seattle biotech company, which emerged on the scene just two… Read More

Juno Therapeutics breaks ground on HQ, establishing a new hub for biotech in Seattle

The groundbreaking for the new headquarters and R&D center of Juno Therapeutics at the Alexandria Center brings increased promise to the… Read More

Shares of Juno Therapeutics jump after Seattle biotech buys X-BODY Inc.

Shares of Juno Therapeutics jumped more than six percent on Tuesday after the Seattle biotechnology company announced its acquisition of… Read More

Juno Therapeutics inks lease for new building in Seattle’s bustling South Lake Union neighborhood

Fast-growing Juno Therapeutics — fresh off its IPO from last December — is expanding its presence in its hometown of… Read More

Fast-growing cancer research company Juno Therapeutics to open Seattle area manufacturing facility

Juno Therapeutics, the fast-growing Seattle biotechnology company, today announced that it plans to open a new manufacturing facility in Bothell… Read More

The best and worst performing tech stocks of 2014 in the Seattle area

It was a busy year for publicly-traded tech companies in the Seattle region, with plenty of winners and losers. The… Read More

Juno Therapeutics’ stock continues to rise after successful IPO

Juno Therapeutics is just a little more than a year old, but the Seattle area biotech startup has quite the… Read More

Juno Therapeutics prices IPO at $24, shares soar in debut

Juno Therapeutics, a heavily-funded cancer research company that was formed just 16 months ago, priced its initial public offering Thursday… Read More

Juno Therapeutics boosts IPO price range to $21 to $23, aims to raise $212M

Juno Therapeutics boosted its IPO range at $21 to $23 per share today as the fast-growing Seattle biotech startup prepares… Read More

Tech Moves: Liz Powell lands at Pro.com; Juno bolsters board ahead of IPO; etc.

—Liz Howekamp Powell, the former vice president of marketing at WhitePages, has landed a new gig as head of organic… Read More

Cancer research startup VentiRx lands $50M

Seattle’s biotech industry has been on an up-and-down roller coaster ride over the past 12 months, with layoffs and R&D… Read More

The top 10 biggest financing deals in the Pacific NW

Juno Therapeutics stunned the startup community earlier this week when it announced $134 million in venture funding, bringing total financing… Read More

New cancer research startup Juno Therapeutics raises $134M to push total funding past $300M

Juno Therapeutics wants to wipe out cancer by rewiring the body’s immune system, and it’s receiving some serious investor backing… Read More

Jeff Bezos-backed Juno Therapeutics closes series A at $176M, appoints new execs

Seattle biotechnology startup Juno Therapeutics, which is developing immunotherapies for cancer, said it has closed its series A financing round… Read More

More funding for cancer research in Seattle: Adaptive Biotechnologies raises $105M

Researchers from Seattle who are finding ways to eliminate cancer are bringing in some serious funding today. On the same… Read More

Tech Moves: INRIX names new board member; Juno taps investment banker as CFO; etc.

—INRIX, the Kirkland company that uses data to reduce traffic congestion, has named Mike Gerling to the board. He previously… Read More

VC dollars surge in NW, propelled by huge $120M deal

Propelled by a massive financing round in upstart Seattle biotechnology company Juno Therapeutics, venture capital investments in the Pacific Northwest… Read More